naltrexone has been researched along with Alcohol Problem in 84 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.19) | 18.2507 |
| 2000's | 22 (26.19) | 29.6817 |
| 2010's | 55 (65.48) | 24.3611 |
| 2020's | 6 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Mason, BJ | 1 |
| Caballeria, E; Gual, A; López-Pelayo, H; Mann, K; Van den Brink, W; Zuluaga, P | 1 |
| de Jong, J; Neven, A; Pieterse, BH | 1 |
| Anton, RF; Falk, DE; Hasin, DS; Heather, N; Kranzler, HR; Litten, RZ; Mann, KF; O'Malley, SS; Witkiewitz, K | 1 |
| Burnette, E; Donato, S; Green, R; Grodin, EN; Lim, AC; Meredith, LR; Ray, LA; Venegas, A | 1 |
| McKee, SA; Ramchandani, VA; Roberts, W; Verplaetse, TL | 1 |
| Bhat, NR; Bierut, LJ; Borodovsky, JT; Grucza, RA; Mintz, CM; Presnall, N; Xu, KY | 1 |
| Gil, A; Guerri, C; Montesinos, J | 1 |
| Lyon, J | 1 |
| De Filippis, S; De Persis, S; De Risio, L; di Giannantonio, M; Di Nicola, M; Janiri, L; Maremmani, AGI; Maremmani, I; Martinotti, G; Pettorruso, M | 1 |
| Behar, E; Coffin, PO; Euren, J; Geier, M; Gleghorn, A; Martin, J; Rowe, C; Santos, GM; Smith-Bernardin, S; Washington, S | 1 |
| Becker, K; Diamant, AL; Ewing, B; Heinzerling, K; Hunter, SB; Lamp, K; Lind, M; Ober, AJ; Osilla, KC; Setodji, CM; Watkins, KE | 1 |
| Bujarski, S; Gillis, A; Green, R; Grodin, E; Hartwell, E; Lim, AC; Miotto, K; Ray, LA; Venegas, A | 1 |
| Bramness, JG; Heldal, AT; Lobmaier, PPK; Skurtveit, S; Vederhus, JK | 1 |
| Harris, AHS; Matson, TE; Williams, EC | 1 |
| Kreek, MJ; Zhou, Y | 1 |
| Brumback, B; Bryant, K; Cook, RL; Espinoza, L; Lewis, JE; Miguez, MJ; Quiros, C; Zhou, Z | 1 |
| Soyka, M | 1 |
| Iheanacho, T; Issa, M; Marienfeld, C; Rosenheck, RA | 1 |
| Arias, AJ; Niciu, MJ | 1 |
| Hallgren, KA; Witkiewitz, K | 1 |
| Amick, HR; Bobashev, G; Feltner, C; Garbutt, JC; Gass, CE; Jonas, DE; Kim, MM; Rowe, CJ; Shanahan, E; Thomas, K; Wines, R | 1 |
| Bujarski, S; Ray, LA | 1 |
| Hendershot, CS | 1 |
| Aballéa, S; Bineau, S; Chalem, Y; François, C; Laramée, P; Millier, A; Rahhali, N; Rehm, J; Toumi, M | 1 |
| Andersen, K; Nielsen, AS; Nielsen, B; Wieben, ES | 2 |
| Fredriksson, I; Jardemark, K; Jayaram-Lindström, N; Nylander, E; Nyström, E; Steensland, P; Wirf, M | 1 |
| Borro, P; Leone, S; Testino, G | 1 |
| Aletraris, L; Bond Edmond, M; Roman, PM | 1 |
| Bowe, T; Del Re, AC; Finlay, AK; Harris, AH; Myrick, HL; Oliva, E; Rubinsky, AD | 1 |
| Crits-Christoph, P; Gallop, R; Gastfriend, DR; Lundy, C; Stringer, M | 1 |
| Arenella, PB; Hendershot, CS; Stoner, SA | 1 |
| Frohe, T; Kirouac, M; Maisto, SA; McCallion, E; Vowles, KE; Witkiewitz, K | 1 |
| Chalk, M; Lubran, R; Mark, TL; McCance-Katz, EF; Richardson, J | 1 |
| Belin, D; Bullmore, ET; Economidou, D; Everitt, BJ; García-Pardo, MP; Giuliano, C; Goodlett, CR; Robbins, TW | 1 |
| Higuchi, S; Yumoto, Y | 1 |
| Helton, SG; Lohoff, FW | 1 |
| Corbin, WR; DeMartini, KS; Fucito, LM; Gueorguieva, R; Kranzler, HR; Leeman, RF; O'Malley, SS | 1 |
| Alanis-Hirsch, K; Chalk, M; Croff, R; Ford, JH; Johnson, K; McCarty, D; Schmidt, L | 1 |
| Addolorato, G; Bernardi, M; Caputo, F; D'Amore, A; Domenicali, M; Maremmani, AG; Maremmani, I; Zoli, G | 1 |
| Bramness, JG; Mann, K; Wurst, FM | 1 |
| Aballéa, S; Brodtkorb, TH; Cristeau, O; Laramée, P; Millier, A; Montgomery, S; Rahhali, N; Rehm, J; Steeves, S; Toumi, M | 1 |
| Bowe, T; Christopher, M; Finlay, AK; Gidwani, R; Hagedorn, H; Harris, AH; Kay, C; Nevedal, A; Rosen, C | 1 |
| Bell, RL; Chambers, RA; Engleman, EA; Greene, MS; Sajid, A; Whiteman, A | 1 |
| Crits-Christoph, P; Gallop, R; Gastfriend, DR; Gibbons, MB; Lundy, C; Markell, HM; Stringer, M | 1 |
| Canidate, SS; Carnaby, GD; Cook, CL; Cook, RL | 1 |
| Bordet, R; Carton, L; Cottencin, O; Gomajee, H; Leroy, A | 1 |
| Arias, AJ; Armeli, S; Covault, J; Gelernter, J; Kallio, A; Karhuvaara, S; Koivisto, T; Kranzler, HR; Mäkelä, R | 1 |
| Andreoli, S; Bria, P; De Filippis, R; Di Giannantonio, M; Di Nicola, M; Janiri, L; Martinotti, G; Mazza, M; Moroni, N; Pomponi, M; Pozzi, G; Reina, D; Romanelli, R; Tedeschi, D | 1 |
| Batki, SL; Carey, K; Cavallerano, M; DeRycke, S; Dimmock, J; Leontieva, L; Meszaros, Z; Ploutz-Snyder, R | 1 |
| Basu, D; Shah, R | 1 |
| Gastfriend, DR; Kranzler, HR; Montejano, LB; Stephenson, JJ; Wang, S | 1 |
| Aldridge, A; Bray, JW; Cisler, RA; Couper, D; McKay, JR; Mills, M; O'Malley, S; Zarkin, GA | 1 |
| Abraham, AJ; Roman, PM | 1 |
| Gastfriend, DR | 1 |
| Abraham, AJ; Knudsen, HK; Roman, PM | 1 |
| Corbin, WR; Fucito, LM; Leeman, RF; O'Malley, SS; Peters, EN; Toll, BA | 1 |
| Hunter-Reel, D; Witkiewitz, K; Zweben, A | 1 |
| Spanagel, R; Vengeliene, V | 1 |
| Clark, DB | 1 |
| Blodgett, JC; Finney, JW; Humphreys, K; Maisel, NC; Wilbourne, PL | 1 |
| Heinz, A; Mann, K; Wilwer, M | 1 |
| Feinn, R; Kranzler, HR; Tennen, H | 1 |
| Kenna, GA; McGeary, JE; Swift, RM | 1 |
| Fuller, BE; Levine, H; McCarty, D; Rieckmann, T; Smith, KW | 1 |
| Williams, SH | 1 |
| Bell, JR; Haber, PS; Morley, KC; Phung, N; Reid, SC; Richardson, K; Sannibale, C; Teesson, M; Thomson, C; Weltman, M | 1 |
| Brady, KT; Tolliver, BK; Verduin, ML | 1 |
| Swift, R | 1 |
| McDonough, KP | 1 |
| Peterson, AM | 1 |
| Brunette, MF; Drake, RE; Green, AI; Noordsy, DL | 1 |
| Funk, D; Juzytsch, W; Lê, AD; Li, Z; Marinelli, PW | 1 |
| Berglund, M; Gorelick, D; Hesselbrock, V; Johnson, BA; Kranzler, HR; Möller, HJ; Soyka, M | 1 |
| Crooks, PA; Hamad, MO; Hammell, DC; Kiptoo, PK; Paudel, KS; Stinchcomb, AL | 1 |
| McMillen, BA | 1 |
| Fiellin, DA; O'Connor, PG; Reid, MC | 1 |
| Hutchison, KE; Monti, PM; Rohsenow, DJ | 1 |
| Tedeschi, M | 1 |
| Volpicelli, JR | 1 |
28 review(s) available for naltrexone and Alcohol Problem
| Article | Year |
|---|---|
Looking Back, Looking Forward: Current Medications and Innovative Potential Medications to Treat Alcohol Use Disorder.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Humans; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); National Institutes of Health (U.S.); United States | 2022 |
Safety of nalmefene for the treatment of alcohol use disorder: an update.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Drug Approval; Humans; Naltrexone; Narcotic Antagonists | 2020 |
[The pharmacological treatment of PTSD and alcohol use disorder: a systematic literature review].
Topics: Alcohol-Related Disorders; Disulfiram; Drug Therapy, Combination; Humans; Naltrexone; Randomized Controlled Trials as Topic; Sertraline; Stress Disorders, Post-Traumatic | 2019 |
A Critical Review of Alcohol Administration Guidelines in Laboratory Medication Screening Research: Is It Time to Include Treatment Seekers?
Topics: Adrenergic alpha-2 Receptor Agonists; Alcohol Deterrents; Alcohol-Related Disorders; Clinical Trials as Topic; Guanfacine; Humans; Naltrexone; Patient Selection | 2021 |
State-of-the-art behavioral and pharmacological treatments for alcohol use disorder.
Topics: Alcohol Deterrents; Alcohol-Related Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Decision Trees; Humans; Naltrexone | 2019 |
Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Clinical Trials as Topic; Disulfiram; Naltrexone; Practice Patterns, Physicians'; Topiramate; United States; United States Department of Veterans Affairs; Veterans | 2019 |
Targeted opioid receptor antagonists in the treatment of alcohol use disorders.
Topics: Alcohol-Related Disorders; Clinical Trials as Topic; Humans; Molecular Targeted Therapy; Naltrexone; Narcotic Antagonists; Receptors, Opioid; Treatment Outcome | 2013 |
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
Topics: Acamprosate; Alcohol-Related Disorders; Fructose; Harm Reduction; Humans; Naltrexone; Outpatients; Randomized Controlled Trials as Topic; Taurine; Topiramate | 2014 |
Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds.
Topics: Alcohol-Related Disorders; Evidence-Based Medicine; Genotype; Humans; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Polymorphism, Single Nucleotide; Precision Medicine; Randomized Controlled Trials as Topic; Receptors, Opioid, mu; Reproducibility of Results | 2014 |
[Alcohol use disorders in elderly people calls for treatment].
Topics: Aged; Aging; Alcohol-Related Disorders; Drug Interactions; Humans; Mass Screening; Motivational Interviewing; Naltrexone; Narcotic Antagonists; Surveys and Questionnaires | 2014 |
Treatment of alcohol dependence: recent progress and reduction of consumption.
Topics: Acamprosate; Age of Onset; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Binge Drinking; Contraindications; Craving; Disulfiram; Drugs, Investigational; Europe; Humans; Meta-Analysis as Topic; Multicenter Studies as Topic; Naltrexone; Neurotransmitter Agents; Randomized Controlled Trials as Topic; Sodium Oxybate; Taurine | 2014 |
[Pharmacological therapies for alcohol use disorder in Japan].
Topics: Acamprosate; Alcohol-Related Disorders; Alcohols; Humans; Japan; Naltrexone; Substance Withdrawal Syndrome; Taurine | 2015 |
Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Anxiety Disorders; Comorbidity; Depressive Disorder, Major; Disulfiram; Fructose; Humans; Naltrexone; Pharmacogenetics; Precision Medicine; Taurine; Topiramate; United States | 2015 |
[Alcohol use disorders in elderly people calls for treatment].
Topics: Aged; Aging; Alcohol-Related Disorders; Drug Interactions; Humans; Mass Screening; Motivational Interviewing; Naltrexone; Narcotic Antagonists; Surveys and Questionnaires | 2015 |
A Systematic Review of Naltrexone for Attenuating Alcohol Consumption in Women with Alcohol Use Disorders.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Female; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome | 2017 |
Intramuscular extended-release naltrexone: current evidence.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2011 |
New pharmacological treatment strategies for relapse prevention.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Animals; Disulfiram; Drugs, Investigational; History, 18th Century; History, 21st Century; Humans; Naltrexone; Receptors, N-Methyl-D-Aspartate; Secondary Prevention; Taurine | 2013 |
Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Ethanol; Humans; Inactivation, Metabolic; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Time Factors; Treatment Outcome | 2013 |
Therapy and supportive care of alcoholics: guidelines for practitioners.
Topics: Alcohol-Related Disorders; Alcoholics Anonymous; Alcoholism; Ambulatory Care Facilities; Counseling; Day Care, Medical; Humans; Motivation; Naltrexone; Practice Guidelines as Topic; Psychotherapy, Brief; Secondary Prevention; Substance Abuse Treatment Centers; Substance Withdrawal Syndrome; Temperance | 2003 |
Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Animals; Clinical Trials as Topic; Disulfiram; Excitatory Amino Acid Antagonists; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2004 |
Medications for treating alcohol dependence.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Disulfiram; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Randomized Controlled Trials as Topic; Serotonin Agents; Taurine; Treatment Outcome | 2005 |
Emerging approaches to managing alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Behavior Therapy; Brain; Disulfiram; Drug Therapy, Combination; Ethanol; Humans; Naltrexone; Taurine | 2007 |
Improving adherence in patients with alcohol dependence: a new role for pharmacists.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Behavior Therapy; Disulfiram; Humans; Naltrexone; Patient Compliance; Pharmacists; Professional Role; Taurine; Treatment Refusal | 2007 |
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Biological Psychiatry; Carbamazepine; Disulfiram; Fructose; Health Planning Guidelines; Humans; Naltrexone; Ondansetron; Societies, Scientific; Substance-Related Disorders; Taurine; Topiramate | 2008 |
New therapies for alcohol problems: application to primary care.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Primary Health Care; Psychotherapy; Research Design; Taurine; United States | 2000 |
Toward bridging the gap between biological, psychobiological and psychosocial models of alcohol craving.
Topics: Alcohol-Related Disorders; Behavior, Addictive; Conditioning, Classical; Cues; Humans; Models, Biological; Models, Psychological; Motivation; Naltrexone; Narcotic Antagonists; Predictive Value of Tests; Reflex, Startle; Treatment Outcome | 2000 |
Naltrexone and acamprosate. Using new drugs for alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Australia; Clinical Trials as Topic; Female; Guidelines as Topic; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Satisfaction; Prognosis; Taurine; Treatment Outcome | 2001 |
Alcohol abuse and alcoholism: an overview.
Topics: Alcohol-Related Disorders; Alcoholism; Attitude to Health; Clinical Trials as Topic; Cost Savings; Female; Health Care Costs; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Compliance; Prevalence; Stereotyping; Treatment Outcome; United States | 2001 |
11 trial(s) available for naltrexone and Alcohol Problem
| Article | Year |
|---|---|
World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Behavior Therapy; Female; Health Surveys; Humans; Male; Mental Health; Middle Aged; Motivational Interviewing; Naltrexone; Risk; Treatment Outcome; United Kingdom; United States; World Health Organization | 2020 |
Reduction in Drinking was Associated With Improved Clinical Outcomes in Women With HIV Infection and Unhealthy Alcohol Use: Results From a Randomized Clinical Trial of Oral Naltrexone Versus Placebo.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Anti-Retroviral Agents; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Middle Aged; Naltrexone; Treatment Outcome; Viral Load | 2019 |
Negative affect is associated with alcohol, but not cigarette use in heavy drinking smokers.
Topics: Adult; Affect; Alcohol-Related Disorders; Benzazepines; Comorbidity; Craving; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Psychiatric Status Rating Scales; Quinoxalines; Smoking; Smoking Cessation; Varenicline; Young Adult | 2014 |
Randomized controlled trial of a mobile phone intervention for improving adherence to naltrexone for alcohol use disorders.
Topics: Adult; Alcohol-Related Disorders; Cell Phone; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Public Health Surveillance; Risk Factors; Surveys and Questionnaires; Text Messaging; Treatment Outcome; Young Adult | 2015 |
Pain as a predictor of heavy drinking and any drinking lapses in the COMBINE study and the UK Alcohol Treatment Trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Behavior Therapy; Chronic Pain; Combined Modality Therapy; Female; Humans; Male; Naltrexone; Pain Measurement; Recurrence; Taurine; Treatment Outcome | 2015 |
Longitudinal findings from a randomized clinical trial of naltrexone for young adult heavy drinkers.
Topics: Adolescent; Adult; Alcohol-Related Disorders; Double-Blind Method; Female; Humans; Longitudinal Studies; Male; Naltrexone; Narcotic Antagonists; Outcome Assessment, Health Care; Young Adult | 2016 |
Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial.
Topics: Adult; Alcohol Withdrawal Delirium; Alcohol-Related Disorders; Anticonvulsants; Anxiety; Calcium Channel Blockers; Double-Blind Method; Female; gamma-Aminobutyric Acid; Hostility; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obsessive-Compulsive Disorder; Pregabalin; Severity of Illness Index; Substance Withdrawal Syndrome | 2010 |
Co-occurring marijuana use is associated with medication nonadherence and nonplanning impulsivity in young adult heavy drinkers.
Topics: Adolescent; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Analysis of Variance; Combined Modality Therapy; Counseling; Female; Humans; Impulsive Behavior; Male; Marijuana Smoking; Medication Adherence; Motivation; Naltrexone; Patient Satisfaction; Psychotherapy; Risk Factors; Young Adult | 2012 |
Does session attendance by a supportive significant other predict outcomes in individual treatment for alcohol use disorders?
Topics: Acamprosate; Adult; Alcohol-Related Disorders; Alcoholism; Behavior Therapy; Combined Modality Therapy; Female; Forecasting; Humans; Male; Middle Aged; Naltrexone; Social Support; Spouses; Taurine; Treatment Outcome | 2012 |
Psychometric properties of the short index of problems as a measure of recent alcohol-related problems.
Topics: Adult; Alcohol-Related Disorders; Alcoholism; Attitude to Health; Connecticut; Counseling; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Personality Inventory; Psychometrics; Sensitivity and Specificity; Social Adjustment | 2003 |
Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Anxiety; Australia; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Placebos; Secondary Prevention; Taurine; Treatment Outcome | 2006 |
45 other study(ies) available for naltrexone and Alcohol Problem
| Article | Year |
|---|---|
Alcohol Cue-Induced Ventral Striatum Activity Predicts Subsequent Alcohol Self-Administration.
Topics: Adult; Alcohol Deterrents; Alcohol-Related Disorders; Aldehyde Dehydrogenase 1 Family; Aldehyde Dehydrogenase, Mitochondrial; Central Nervous System Depressants; Cues; Ethanol; Female; Functional Neuroimaging; Genotype; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Male; Multilevel Analysis; Naltrexone; Proportional Hazards Models; Random Allocation; Receptors, Opioid, mu; Self Administration; Thalamus; Ventral Striatum; Young Adult | 2020 |
Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
Topics: Accidental Falls; Adult; Alcohol-Related Disorders; Alcoholism; Analgesics, Opioid; Buprenorphine; Central Nervous System Depressants; Drug Overdose; Ethanol; Female; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Protective Factors; Wounds and Injuries; Young Adult | 2021 |
Nalmefene Prevents Alcohol-Induced Neuroinflammation and Alcohol Drinking Preference in Adolescent Female Mice: Role of TLR4.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Animals; Astrocytes; Cell Death; Chemokines; Drug Evaluation, Preclinical; Ethanol; Female; Membrane Microdomains; Mice, Inbred C57BL; Mice, Knockout; Myelin Sheath; Naloxone; Naltrexone; Narcotic Antagonists; Primary Cell Culture; Toll-Like Receptor 4 | 2017 |
More Treatments on Deck for Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Amines; Baclofen; Cyclohexanecarboxylic Acids; Cytidine Diphosphate Choline; Disulfiram; Drug Repositioning; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Mifepristone; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); Off-Label Use; Patient Acceptance of Health Care; Taurine; Topiramate; United States; Varenicline | 2017 |
Nalmefene in Alcohol Use Disorder Subjects with Psychiatric Comorbidity: A Naturalistic Study.
Topics: Adult; Alcohol-Related Disorders; Alcoholism; Comorbidity; Female; Humans; Male; Mental Disorders; Middle Aged; Naltrexone; Narcotic Antagonists | 2017 |
Low-threshold extended-release naltrexone for high utilizers of public services with severe alcohol use disorder: A pilot study.
Topics: Alcohol Deterrents; Alcohol-Related Disorders; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Naltrexone; Patient Acceptance of Health Care; Pilot Projects; Quality of Life | 2018 |
Assessing and improving organizational readiness to implement substance use disorder treatment in primary care: findings from the SUMMIT study.
Topics: Adult; Alcohol-Related Disorders; Attitude of Health Personnel; Buprenorphine; Cognitive Behavioral Therapy; Delayed-Action Preparations; Delivery of Health Care; Feasibility Studies; Female; Financing, Government; Humans; Los Angeles; Male; Middle Aged; Motivational Interviewing; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Primary Health Care; United States | 2017 |
Use of drugs for alcohol use disorder in Norway 2004–16.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Drug Prescriptions; Drug Utilization; Female; Humans; Male; Middle Aged; Naltrexone; Norway; Registries | 2018 |
Combination of Clinically Utilized Kappa-Opioid Receptor Agonist Nalfurafine With Low-Dose Naltrexone Reduces Excessive Alcohol Drinking in Male and Female Mice.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Animals; Drug Evaluation, Preclinical; Drug Tolerance; Female; Male; Mice, Inbred C57BL; Morphinans; Naltrexone; Receptors, Opioid, kappa; Saccharin; Spiro Compounds; Sucrose | 2019 |
Review: In alcohol use disorders, acamprosate is more effective for inducing abstinence while naltrexone is more effective for reducing heavy drinking and craving.
Topics: Alcohol Deterrents; Alcohol-Related Disorders; Humans; Naltrexone; Narcotic Antagonists; Taurine | 2013 |
Long-acting injectable depot naltrexone use in the Veterans' Health Administration: a national study.
Topics: Alcohol-Related Disorders; Comorbidity; Delayed-Action Preparations; Diagnosis, Dual (Psychiatry); Drug Prescriptions; Drug Utilization; Female; Hospitalization; Humans; Logistic Models; Male; Mental Disorders; Mental Health Services; Middle Aged; Multivariate Analysis; Naltrexone; Narcotic Antagonists; Psychiatric Department, Hospital; Rural Population; Socioeconomic Factors; Substance-Related Disorders; United States; United States Department of Veterans Affairs; Urban Population; Veterans | 2014 |
Missing data in alcohol clinical trials: a comparison of methods.
Topics: Alcohol-Related Disorders; Bias; Data Collection; Humans; Naltrexone; Narcotic Antagonists; Patient Dropouts; Randomized Controlled Trials as Topic; Recurrence | 2013 |
KASL clinical practice guidelines: management of alcoholic liver disease.
Topics: Alcohol Abstinence; Alcohol Drinking; Alcohol-Related Disorders; Baclofen; Disulfiram; Fatty Liver, Alcoholic; Hepatitis, Alcoholic; Humans; Liver Cirrhosis; Liver Diseases, Alcoholic; Naltrexone; Prevalence; Prognosis; Risk Factors; Severity of Illness Index; Surveys and Questionnaires | 2013 |
A predictive microsimulation model to estimate the clinical relevance of reducing alcohol consumption in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Computer Simulation; England; Female; Harm Reduction; Humans; Logistic Models; Male; Middle Aged; Models, Theoretical; Naltrexone; Narcotic Antagonists; Wounds and Injuries | 2014 |
Evaluation of guanfacine as a potential medication for alcohol use disorder in long-term drinking rats: behavioral and electrophysiological findings.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Animals; Central Nervous System Depressants; Choice Behavior; Conditioning, Operant; Disease Models, Animal; Drug Evaluation, Preclinical; Drug-Seeking Behavior; Ethanol; Glutamic Acid; Guanfacine; Male; Naltrexone; Prefrontal Cortex; Pyramidal Cells; Rats, Wistar; Tissue Culture Techniques; Treatment Outcome | 2015 |
Adoption of injectable naltrexone in U.S. substance use disorder treatment programs.
Topics: Alcohol-Related Disorders; Humans; Naltrexone; Opioid-Related Disorders; Substance Abuse Treatment Centers; United States | 2015 |
Extended release naltrexone for alcohol use disorders: quasi-experimental effects on mortality and subsequent detoxification episodes.
Topics: Alcohol-Related Disorders; Comorbidity; Delayed-Action Preparations; Female; Humans; Logistic Models; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome; United States; United States Department of Veterans Affairs | 2015 |
Extended-Release Naltrexone for Alcohol and Opioid Problems in Missouri Parolees and Probationers.
Topics: Adult; Alcohol-Related Disorders; Criminals; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Missouri; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outcome Assessment, Health Care | 2015 |
Medicaid coverage of medications to treat alcohol and opioid dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Buprenorphine, Naloxone Drug Combination; Humans; Insurance Coverage; Medicaid; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Taurine; United States | 2015 |
The Novel μ-Opioid Receptor Antagonist GSK1521498 Decreases Both Alcohol Seeking and Drinking: Evidence from a New Preclinical Model of Alcohol Seeking.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Animals; Blood Alcohol Content; Choice Behavior; Conditioning, Operant; Cues; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug-Seeking Behavior; Indans; Male; Naltrexone; Narcotic Antagonists; Rats; Receptors, Opioid, mu; Reinforcement, Psychology; Species Specificity; Triazoles | 2015 |
Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use.
Topics: Alcohol-Related Disorders; Delayed-Action Preparations; Humans; Insurance, Health, Reimbursement; Interviews as Topic; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Qualitative Research; United States | 2016 |
Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: A case series.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Alcohols; Craving; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Sodium Oxybate; Treatment Outcome | 2016 |
Marketing Status and Perceived Efficacy of Drugs for Supporting Abstinence and Reducing Alcohol Intake in Alcohol Use Disorders: A Survey among European Federation of Addiction Societies in Europe.
Topics: Acamprosate; Alcohol Abstinence; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Europe; Humans; Marketing; Naltrexone; Narcotic Antagonists; Perception; Practice Guidelines as Topic; Societies, Medical; Surveys and Questionnaires; Taurine; Treatment Outcome | 2016 |
A Comparison of Markov and Discrete-Time Microsimulation Approaches: Simulating the Avoidance of Alcohol-Attributable Harmful Events from Reduction of Alcohol Consumption Through Treatment of Alcohol Dependence.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Female; Humans; Naltrexone | 2016 |
Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Female; Fructose; Humans; Male; Middle Aged; Naltrexone; Patient Compliance; Taurine; Topiramate; United States; United States Department of Veterans Affairs; Veterans; Young Adult | 2016 |
Prescription drug monitoring program data tracking of opioid addiction treatment outcomes in integrated dual diagnosis care involving injectable naltrexone.
Topics: Adult; Alcohol-Related Disorders; Analgesics, Opioid; Diagnosis, Dual (Psychiatry); Female; Humans; Injections, Intravenous; Longitudinal Studies; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prescription Drug Monitoring Programs; Substance Abuse Detection; Treatment Outcome | 2016 |
A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Missouri; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outcome Assessment, Health Care; Psychotherapy; Taurine | 2016 |
Naltrexone in the treatment of binge eating disorder in a patient with severe alcohol use disorder: a case report.
Topics: Alcohol-Related Disorders; Binge-Eating Disorder; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists | 2017 |
Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers.
Topics: Adult; Alcohol-Related Disorders; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Receptors, Opioid; Treatment Outcome | 2008 |
Patient and provider attitudes towards monitored naltrexone treatment of alcohol dependence in schizophrenia.
Topics: Adult; Alcohol-Related Disorders; Attitude of Health Personnel; Clinical Trials as Topic; Counseling; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Patient Satisfaction; Schizophrenia; Substance Abuse Treatment Centers; Surveys and Questionnaires; Treatment Outcome | 2009 |
Topiramate: 'small is beautiful'?
Topics: Alcohol Deterrents; Alcohol-Related Disorders; Fructose; Humans; Naltrexone; Topiramate; Treatment Outcome | 2009 |
Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Alcoholics; Alcoholism; Anticonvulsants; Baclofen; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; France; Fructose; Health Status; Humans; Naltrexone; Psychotherapy; Randomized Controlled Trials as Topic; Secondary Prevention; Self-Help Groups; Social Support; Taurine; Temperance; Topiramate; Treatment Outcome | 2009 |
Effects of naltrexone treatment for alcohol-related disorders on healthcare costs in an insured population.
Topics: Administration, Oral; Adult; Alcohol-Related Disorders; Case-Control Studies; Female; Health Care Costs; Humans; Insurance, Health; Male; Middle Aged; Multivariate Analysis; Naltrexone; Narcotic Antagonists | 2010 |
The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE study.
Topics: Acamprosate; Accidents, Traffic; Alcohol Deterrents; Alcohol-Related Disorders; Behavior Therapy; Costs and Cost Analysis; Crime; Health Services; Humans; Naltrexone; Taurine | 2010 |
Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector.
Topics: Alcohol Deterrents; Alcohol-Related Disorders; Data Collection; Diffusion of Innovation; Health Knowledge, Attitudes, Practice; Humans; Injections; Logistic Models; Medication Adherence; Multivariate Analysis; Naltrexone; Practice Patterns, Physicians'; Private Sector; Substance Abuse Treatment Centers; United States | 2010 |
Treating depression along with alcohol dependence.
Topics: Alcohol-Related Disorders; Depression; Health Knowledge, Attitudes, Practice; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic | 2010 |
A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuation.
Topics: Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Databases, Factual; Disulfiram; Drug Utilization; Ethanol; Humans; Longitudinal Studies; Naltrexone; Practice Patterns, Physicians'; Substance Abuse Treatment Centers; Time Factors | 2011 |
Pharmacotherapy for adolescent alcohol use disorder.
Topics: Acamprosate; Adolescent; Alcohol-Related Disorders; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Central Nervous System Stimulants; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Disulfiram; Humans; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders; Taurine | 2012 |
Adoption of naltrexone to treat alcohol dependence.
Topics: Alcohol-Related Disorders; Ambulatory Care Facilities; Female; Health Surveys; Humans; Male; Naltrexone; Narcotic Antagonists; Substance Abuse Treatment Centers; United States | 2005 |
Alcohol use and anxiety: diagnostic and management issues.
Topics: Adult; Alcohol-Related Disorders; Anxiety Disorders; Combined Modality Therapy; Comorbidity; Female; Humans; Life Change Events; Naltrexone; Narcotic Antagonists; Personality Inventory; Psychotherapy; Surveys and Questionnaires; Temperance | 2007 |
Alcohol dependence and pharmacologic treatment. Introduction.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Humans; Naltrexone; Taurine; United States | 2007 |
Schizophrenia and co-occurring substance use disorder.
Topics: Acamprosate; Adult; Alcohol-Related Disorders; Antipsychotic Agents; Comorbidity; Diagnosis, Dual (Psychiatry); Disulfiram; Humans; Ill-Housed Persons; Male; Naltrexone; Schizophrenia; Substance-Related Disorders; Taurine | 2007 |
Effects of opioid receptor blockade on the renewal of alcohol seeking induced by context: relationship to c-fos mRNA expression.
Topics: Alcohol-Related Disorders; Alcohols; Analysis of Variance; Animals; Autoradiography; Behavior, Animal; Brain; Conditioning, Operant; Extinction, Psychological; Male; Naltrexone; Narcotic Antagonists; Physical Stimulation; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Receptors, Opioid; RNA, Messenger; Self Administration | 2007 |
In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs.
Topics: Administration, Cutaneous; Alcohol-Related Disorders; Animals; Bupropion; Chromatography, High Pressure Liquid; Drug Delivery Systems; Female; Guinea Pigs; Male; Mass Spectrometry; Molecular Structure; Naltrexone; Prodrugs; Skin; Skin Absorption; Skin Irritancy Tests; Smoking Cessation | 2008 |
Drug abuse and therapy.
Topics: Alcohol-Related Disorders; Animals; Anti-Anxiety Agents; Antipsychotic Agents; Clinical Trials as Topic; Drug Industry; Humans; Naltrexone; National Institutes of Health (U.S.); Substance-Related Disorders; United States | 1998 |